ME3

Across TCGA pan-cancer cohorts, ME3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ME3 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ME3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ME3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

UCEC, LSCC, and PDAC are the cancer types where ME3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	II,III,IV	0.450	1.000	.018	24	view →
LSCC	DFS	Quartile	III,IV	0.266	1.000	.002	12	view →
PDAC	OS	Tertile	IV	0.973	0.490	.024	11	view →
CCRCC	OS	Median	II,III,IV	0.616	0.871	.013	5	view →
OV	DFS	Median	All	0.600	0.972	.025	4	view →
HNSC	DFS	Quartile	IV	0.869	0.515	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ME3–UCEC (DFS)

Open the UCEC breakdown →